company background image
EXAS

Exact Sciences NasdaqCM:EXAS Stock Report

Last Price

US$65.66

Market Cap

US$12.1b

7D

-0.2%

1Y

44.1%

Updated

04 Dec, 2023

Data

Company Financials +

Exact Sciences Corporation

NasdaqCM:EXAS Stock Report

Mkt Cap: US$12.1b

EXAS Stock Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.

About the company

EXAS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 39.2% below our estimate of its fair value
Earnings are forecast to grow 65.43% per year
Trading at good value compared to peers and industry

Risk Analysis

No risks detected for EXAS from our risk checks.

Exact Sciences Corporation Competitors

Neurocrine Biosciences

NasdaqGS:NBIX

US$11.5b

United Therapeutics

NasdaqGS:UTHR

US$11.3b

Incyte

NasdaqGS:INCY

US$12.1b

Legend Biotech

NasdaqGS:LEGN

US$10.9b

Price History & Performance

Summary of all time highs, changes and price drops for Exact Sciences
Historical stock prices
Current Share PriceUS$65.66
52 Week HighUS$100.77
52 Week LowUS$43.90
Beta1.46
1 Month Change-2.03%
3 Month Change-20.60%
1 Year Change44.15%
3 Year Change-51.31%
5 Year Change-5.59%
Change since IPO345.15%

Recent News & Updates

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Recent updates

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Jun 15
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Apr 26
Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Feb 23
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Jan 10
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?

Oct 31
Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?

Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans

Oct 13

Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely

Aug 15

Exact Sciences GAAP EPS of -$0.94 beats by $0.14, revenue of $521.64M beats by $25.5M

Aug 02

Exact Sciences Won't Likely Escape Consolidation In The Industry

May 25

Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation

May 14

A First Take On Exact Sciences

Feb 16

Exact Sciences Is A Pass Based On Its Intrinsic Value

Dec 10

Exact Sciences: On Point In A Bearish Market

Sep 22

Making Sense Of The Possible Merger Between Exact Sciences And Invitae

Aug 14

Cathie Wood’s ARK ETF raises stake in Exact Sciences

Jun 01

Exact Sciences Corporation 2021 Q1 - Results - Earnings Call Presentation

May 05

Exact Sciences: New Acqusitions Aim To Unlock Strategic Value

Apr 26

Shareholder Returns

EXASUS BiotechsUS Market
7D-0.2%3.8%0.9%
1Y44.1%-5.8%13.6%

Return vs Industry: EXAS exceeded the US Biotechs industry which returned -5.8% over the past year.

Return vs Market: EXAS exceeded the US Market which returned 13.6% over the past year.

Price Volatility

Is EXAS's price volatile compared to industry and market?
EXAS volatility
EXAS Average Weekly Movement6.5%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: EXAS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: EXAS's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19956,350Kevin Conroyhttps://www.exactsciences.com

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Exact Sciences Corporation Fundamentals Summary

How do Exact Sciences's earnings and revenue compare to its market cap?
EXAS fundamental statistics
Market CapUS$12.12b
Earnings (TTM)-US$282.13m
Revenue (TTM)US$2.41b

4.9x

P/S Ratio

-42.1x

P/E Ratio

Is EXAS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
EXAS income statement (TTM)
RevenueUS$2.41b
Cost of RevenueUS$629.54m
Gross ProfitUS$1.78b
Other ExpensesUS$2.06b
Earnings-US$282.13m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.56
Gross Margin73.83%
Net Profit Margin-11.73%
Debt/Equity Ratio75.7%

How did EXAS perform over the long term?

See historical performance and comparison